Navigation Links
Adlyfe Appoints Roxanne Duan as Vice President of Research
Date:9/17/2007

ROCKVILLE, Md., Sept. 17 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Roxanne Duan, Ph.D. as Vice President of Research. Dr. Duan will be responsible for overseeing the Adlyfe's Research efforts and will report directly to the Chief Executive Officer.

Duan comes to Adlyfe with nearly two decades of experience. Most recently, Dr. Duan served as Vice President of Research at Functional Genetics, Inc., where she made major impact on developing antibody therapeutics for infectious diseases and improving a gene perturbation technology that facilitated drug target discovery and validation. Prior to Functional Genetics, Dr. Duan was the project leader and co-inventor of several clinical protein therapeutic candidates at Human Genome Sciences (HGS), covering areas of cardiovascular diseases, wound repair, and diabetes. In addition, she holds more than 20 issued patents in the area of protein therapeutics and more than 25 peer reviewed publications.

Dr. Duan began her career as a Senior Research Fellow at the National Cancer Institute where she studied tumor suppressor genes. She received her B.Sc. in Pharmacy from National Taiwan University and her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and worked as a postdoctoral fellow at the Howard Hughes Medical Research Institute at the University of California, San Francisco, on growth factors and their application in cardiovascular diseases.

Alan Rudolph, President and CEO of Adlyfe, said, "We are delighted that Roxanne has joined Adlyfe in this important new role. Her experience brings a critical skill set to our rapidly growing diagnostic product development activities. Her experience in protein biochemistry and development of protein based assays be instrumental to our efforts to develop diagnostic assays for neurodegenerative diseases such as Alzheimer's disease. As the Company enters its next phase of growth, we are excited to have her on board to support our efforts to develop this novel technology and deliver it to the marketplace."

Roxanne Duan commented, "I am excited to become a part of Adlyfe and to join its excellent research team. I look forward to contributing to the development of this truly novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain diseases."

About Adlyfe

Adlyfe Inc. was established early in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain and amyloid diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease, Huntington's disease, systemic amyloidosis, diabetes and other diseases.

The Company's novel technology is based on the synthesis of small peptide, or Pronucleon (TM) ligands, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid aggregation (and eventual amyloid plaque formation). These aggregates are associated with disease state progression in a number of brain-wasting and amyloid diseases.

Adlyfe, a privately-held corporation, was initially funded by the Defense Advanced Research Projects Agency (DARPA), the U.S. Army Medical Research and Materiel Command, the National Heart, Lung and Blood Institute, and Britain's Department for Environment, Food and Rural Affairs. More recently, Adlyfe raised additional funding with venture capital firms Canaan Venture Partners and Burrill Associates.

Internet Website: http://www.adlyfe.com

Media:

Janine McCargo

1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Adlyfe
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President ... the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. ... in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, EarQ ... the unique opportunity to learn more about Signia’s technology and the successful business and ... is our priority to see practices succeed in this highly competitive industry,” said Ed ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing company in ... 35 years. Maintaining core values of exceptional customer service, quality work at reasonable rates, ... leading name in San Diego plumbing, and other services including heating & air conditioning ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
Breaking Medicine Technology: